Clinical Trials Logo

Clinical Trial Summary

The project will amalgamate data from several large Indian centers to describe the genotype, clinical spectrum, natural course, genotype-phenotype correlation, outcome, and response to medical therapy in Indian children with progressive familial intrahepatic cholestasis (PFIC). This will be the first such Indian registry of children with PFIC. There are currently limited single-center studies describing the genotype, natural course, and outcome of Indian children with PFIC. Data will be collected retrospectively from the participating centers across the country. Only genetically confirmed cases would be included.


Clinical Trial Description

There is a lack of robust literature from India on PFIC. The study would be the first to extensively describe the genotype of Indian children with PFIC and their natural course. Being a multicentric study, the results generated would therefore be applicable to the whole of the country. Understanding the prevalent genotypes in the Indian population and their related phenotype would help both the individual management decisions of these patients and further policy-making for their diagnosis and treatment. With the advent of genetic diagnosis through sequencing techniques and these tests becoming more affordable, every Indian center is now diagnosing a fair number of these cases which used to go undiagnosed previously. This has changed the landscape of cholestatic liver disease in children where PFICs are now the most prevalent pediatric cholestatic disorder. European studies have demonstrated 2 common mutations where patients respond very well to surgical biliary diversion and have good native liver survival. These mutations have rarely been reported in India. Results from this study could thus guide appropriate decision-making based on outcome and help choose the modality of treatment for the individual patient - medical, surgical biliary diversion, or liver transplantation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05704517
Study type Observational
Source Institute of Liver and Biliary Sciences, India
Contact Bikrant B Lal, MD, DM
Phone +919540951063
Email bikrant18may@gmail.com
Status Recruiting
Phase
Start date January 28, 2023
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04729751 - A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Phase 2
Active, not recruiting NCT03659916 - Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC Phase 3
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT04071197 - Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders N/A
Completed NCT02131623 - Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
Completed NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 Phase 1
Completed NCT03082937 - An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects Phase 1
Enrolling by invitation NCT03930810 - NAtural Course and Prognosis of PFIC and Effect of Biliary Diversion
Approved for marketing NCT04483531 - Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis